P48 is a predictive marker for outcome of postoperative interferon-α treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma
P48 is a predictive marker for outcome of postoperative interferon-α treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma
复制标题
DOI：
10.1002/cncr.22206
复制
发表时间：
2006-10-01
期刊：
影响因子：
6.2
通讯作者：
Sun, Hui-Chuan
中科院分区：
文献类型：
--
作者：
Qian, Yong-Bing;Zhang, Ju-Bo;Sun, Hui-Chuan
背景术后α-干扰素（IFN-α）治疗改善了B型肝炎病毒（HBV）相关肝细胞癌（HCC）患者的生存率。结果的预测标志物的识别将有助于选择最有可能从治疗中获益的患者。对从随机试验中接受术后IFN-α治疗（第1组; n = 80例患者）和未接受术后IFN-α治疗（第2组; n = 75例患者）的患者中采集的标本进行P48的免疫组织化学研究。P48阳性表达分级为>= 20%阳性细胞。81例P48阳性，74例P48阴性。P48阴性和P48阳性患者的临床病理学数据具有可比性。第1组中P48阳性患者的无病生存期（DFS）和总生存期（OS）优于P48阴性患者（DFS，P =.036; OS，P =.014），然而，第2组中P48阳性和阴性患者的DFS和OS无差异。第I组P48阳性患者的OS优于第2组P48阳性患者（OS，P = 0.001），但当P48阴性时无差异。在第1组中，DFS的危险因素是肝硬化和P48染色，OS的危险因素是肿瘤分化和P48染色。受试者工作曲线分析表明，在DFS的前2年，联合肝硬化和P48具有良好的预测准确性;在OS的前4年，联合肿瘤分化和P48具有良好的预测准确性。P48可作为HBV相关HCC患者术后IFN-α治疗后预后的预测指标。
BACKGROUND. Postoperative interferon-alpha (IFN-alpha) therapy improved survival in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). The identification of predictive markers of outcome will help to select patients who are most likely to benefit from treatment.METHODS. An immunnhistochemical study of P48 was performed on specimens that were collected from patients in a randomized trial who received postoperative IFN-alpha therapy (Group 1; n = 80 patients) and who did not receive postoperative IFN-alpha therapy (Group 2; n = 75 patients). Positive P48 expression was graded as >= 20% positive cells in 1 sample.RESULTS. Eighty-one patients were positive for P48, and 74 patients were negative for P48. The clinicopathologic data were comparable between patients with P48-negative and P48-positive staining. Disease-free survival (DFS) and overall survival (OS) in P48-positive patients were better than that in P48-negative patients in Group 1 (DFS, P =.036; OS, P =.014), however, DFS and OS did not differ between patients with positive and negative P48 in Group 2. OS in P48-positive patients from Group I was better than that in patients with P48-positive patients from Group 2 (OS, P =.001) but did not differ when P48 was negative. In Group 1, the risk factors for DFS were cirrhosis and P48 staining, and the risk factors for OS were tumor differentiation and P48 staining. Receiver operating curve analysis indicated that, in the first 2 years of DFS, combined cirrhosis and P48 had good predictive accuracy; and, in the first 4 years of OS, combined tumor differentiation and P48 had good predictive accuracy.CONCLUSIONS. P48 was useful as a predictive marker of outcome after postoperative IFN-alpha treatment in patients with HBV-related HCC.